Epidermal growth factor receptor vIII expression in U87 glioblastoma cells alters their proteasome composition, function, and response to irradiation Journal Article


Authors: Kim, K.; Brush, J. M.; Watson, P. A.; Cacalano, N. A.; Iwamoto, K. S.; McBride, W. H.
Article Title: Epidermal growth factor receptor vIII expression in U87 glioblastoma cells alters their proteasome composition, function, and response to irradiation
Abstract: Little is known about the factors that influence the proteasome structures in cells and their activity, although this could be highly relevant to cancer therapy. We have previously shown that, within minutes, irradiation inhibits substrate degradation by the 26S proteasome in most cell types. Here, we report an exception in U87 glioblastoma cells transduced to express the epidermal growth factor receptor vIII (EGFRvIII) mutant (U87EGFRvIII), which does not respond to irradiation with 26S proteasome inhibition. This was assessed using either a fluorogenic substrate or a reporter gene, the ornithine decarboxylase degron fused to ZsGreen (cODCZsGreen), which targets the protein to the 26S proteasome. To elucidate whether this was due to alterations in proteasome composition, we used quantitative reverse transcription-PCR to quantify the constitutive (X, Y, Z) and inducible 20S subunits (Lmp7, Lmp2, Mecl1), and 11S (PA28α and β) and 19S components (PSMC1 and PSMD4). U87 and U87EGFRvIII significantly differed in expression of proteasome subunits, and in particular immunosubunits. Interestingly, 2 Gy irradiation of U87 increased subunit expression levels by 16% to 324% at 6 hours, with a coincident 30% decrease in levels of the proteasome substrate c-myc, whereas they changed little in U87EGFRvIII. Responses similar to 2 Gy were seen in U87 treated with a proteasome inhibitor, NPI0052, suggesting that proteasome inhibition induced replacement of subunits independent of the means of inhibition. Our data clearly indicate that the composition and function of the 26S proteasome can be changed by expression of the EGFRvIII. How this relates to the increased radioresistance associated with this cell line remains to be established. Copyright © 2008 American Association for Cancer Research.
Keywords: controlled study; protein expression; unclassified drug; human cell; cancer radiotherapy; flow cytometry; brain neoplasms; protein function; protein analysis; reverse transcription polymerase chain reaction; proteasome; proteasome inhibitor; enzyme inhibition; proteasome endopeptidase complex; microscopy, confocal; protein targeting; epidermal growth factor receptor; green fluorescent protein; receptor, epidermal growth factor; cancer cell culture; cell line, tumor; gene expression regulation, neoplastic; recombinant fusion proteins; reverse transcriptase polymerase chain reaction; quantitative analysis; glioblastoma; myc protein; reporter gene; radiosensitivity; dna primers; protein subunit; oncogene c myc; salinosporamide a; retroviridae; epidermal growth factor receptor 8; ornithine decarboxylase
Journal Title: Molecular Cancer Research
Volume: 6
Issue: 3
ISSN: 1541-7786
Publisher: American Association for Cancer Research  
Date Published: 2008-03-01
Start Page: 426
End Page: 434
Language: English
DOI: 10.1158/1541-7786.mcr-07-0313
PUBMED: 18337449
PROVIDER: scopus
PMCID: PMC2877368
DOI/URL:
Notes: --- - "Cited By (since 1996): 6" - "Export Date: 17 November 2011" - "CODEN: MCROC" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Philip A Watson
    26 Watson